Vanguard Group
STAB

Vanguard Group’s Statera Biopharma, Inc. Common Stock STAB Stock Holding History

Vanguard Group’s Portfolio STAB Stock Details STAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-378,677
Closed -$30.7K – 4654
2022
Q4 		$30.7K Hold
378,677
– – ﹤0.01% 4474
2022
Q3 		$49K Sell
378,677
-10,433
-3% -$2.2K ﹤0.01% 4548
2022
Q2 		$111K Hold
389,110
– – ﹤0.01% 4536
2022
Q1 		$122K Sell
389,110
-28,249
-7% -$30.2K ﹤0.01% 4583
2021
Q4 		$960K Sell
417,359
-8,982
-2% -$26.5K ﹤0.01% 4277
2021
Q3 		$984K Buy
426,341
+328,806
+337% +$1.25M ﹤0.01% 4249
2021
Q2 		$533K Buy
97,535
+29,443
+43% +$159K ﹤0.01% 4260
2021
Q1 		$357K Buy
68,092
+15,500
+29% +$84.8K ﹤0.01% 4182
2020
Q4 		$181K Hold
52,592
– – ﹤0.01% 4099
2020
Q3 		$104K Hold
52,592
– – ﹤0.01% 4012
2020
Q2 		$135K Hold
52,592
– – ﹤0.01% 3963
2020
Q1 		$88K Buy
52,592
+17,639
+50% +$36K ﹤0.01% 3959
2019
Q4 		$21K Sell
34,953
-18,132
-34% -$13.4K ﹤0.01% 4088
2019
Q3 		$54K Buy
53,085
+211
+0.4% +$284 ﹤0.01% 4080
2019
Q2 		$77K Sell
52,874
-53,800
-50% -$83.3K ﹤0.01% 4072
2019
Q1 		$176K Hold
106,674
– – ﹤0.01% 3947
2018
Q4 		$108K Sell
106,674
-63,673
-37% -$110K ﹤0.01% 3991
2018
Q3 		$342K Hold
170,347
– – ﹤0.01% 3915
2018
Q2 		$419K Hold
170,347
– – ﹤0.01% 3850
2018
Q1 		$514K Buy
170,347
+13,101
+8% +$46.2K ﹤0.01% 3780
2017
Q4 		$631K Sell
157,246
-12,842
-8% -$39K ﹤0.01% 3696
2017
Q3 		$586K Hold
170,088
– – ﹤0.01% 3714
2017
Q2 		$501K Buy
170,088
+87,885
+107% +$287K ﹤0.01% 3726
2017
Q1 		$132K Hold
82,203
– – ﹤0.01% 3964
2016
Q4 		$117K Hold
82,203
– – ﹤0.01% 3962
2016
Q3 		$143K Sell
82,203
-5,815
-7% -$12.8K ﹤0.01% 3948
2016
Q2 		$248K Hold
88,018
– – ﹤0.01% 3908
2016
Q1 		$223K Buy
88,018
+500
+0.6% +$1.68K ﹤0.01% 3938
2015
Q4 		$306K Sell
87,518
-1,065
-1% -$4.29K ﹤0.01% 3937
2015
Q3 		$385K Buy
88,583
+5,400
+6% +$22K ﹤0.01% 3919
2015
Q2 		$361K Buy
83,183
+1,135
+1% +$3.42K ﹤0.01% 3946
2015
Q1 		$295K Buy
82,048
+11,446
+16% +$47K ﹤0.01% 3935
2014
Q4 		$402K Sell
70,602
-1,544
-2% -$12.1K ﹤0.01% 3789
2014
Q3 		$662K Buy
72,146
+1,965
+3% +$18K ﹤0.01% 3635
2014
Q2 		$674K Buy
70,181
+1,687
+2% +$19.7K ﹤0.01% 3601
2014
Q1 		$933K Buy
68,494
+1,245
+2% +$20.3K ﹤0.01% 3477
2013
Q4 		$1.57M Hold
67,249
– – ﹤0.01% 3289
2013
Q3 		$2.1M Buy
67,249
+78
+0.1% +$2.58K ﹤0.01% 3112
2013
Q2 		$2.12M Buy
+67,171
New +$2.31M ﹤0.01% 3047

Other funds holding STAB

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
TAM
Tucker Asset Management Littleton, Colorado $343M AUM 17.55% 1-Year Est. Return

Vanguard Group's STAB Position: Q1 2023 in Review

Vanguard Group sold out of Statera Biopharma, Inc. Common Stock (STAB) in Q1 2023, closing a stake of 378,677 shares — an estimated $30.7K sold.

Vanguard Group first reported a position in STAB in Q2 2013 and held it in 39 quarters. The position peaked at $2.12M in Q2 2013. 4 funds tracked by Wall St. Rank hold STAB as of Q1 2023.

  • Vanguard Group reported no remaining Statera Biopharma, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Vanguard Group sold 378,677 Statera Biopharma, Inc. Common Stock shares in Q1 2023, an estimated $30.7K.
  • Vanguard Group first reported a position in Statera Biopharma, Inc. Common Stock in Q2 2013 and held it in 39 quarters.
  • Vanguard Group's Statera Biopharma, Inc. Common Stock position peaked at $2.12M in Q2 2013.
  • 4 funds tracked by Wall St. Rank held Statera Biopharma, Inc. Common Stock as of Q1 2023.

Based on Vanguard Group's 13F filing for Q1 2023, filed 15 May 2023.